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Introduction
The treatment of advanced melanoma has improved dramatically in the last decade. However, improving outcomes in patients with central nervous system (CNS) metastases remains a critical challenge, particularly among those with metastatic spread to the leptomeninges (leptomeningeal disease, or LMD). The median survival of patients with LMD is only 6-10 weeks, which is significantly worse compared to patients with three or more parenchymal brain metastases. (1, 2) Treatment options for patients with LMD are very limited, and there is minimal evidence of clinical benefit. (3, 4) Multiple immunotherapies can achieve durable disease control in patients with metastatic melanoma. However, little data is available about the safety and efficacy of these treatments among patients with LMD. Here we describe, to our knowledge, the first intrathecal administration of autologous tumor infiltrating lymphocytes (TIL) in combination with intrathecal interleukin-2 (IT IL-2) in a metastatic melanoma patient with LMD. Our results demonstrate the safety and feasibility of this therapy and provide support for prospective clinical testing in this challenging patient population.
Case Presentation
At initial melanoma presentation, a healthy 52-year-old male was diagnosed with a cutaneous melanoma to the right cheek on shave biopsy (Clark's level reported at least III, Breslow thickness at least 0.84 mm). He underwent wide local excision (residual melanoma depth 1.49mm) and sentinel lymph node biopsy, which revealed melanoma in three out of four parotid lymph nodes. He subsequently underwent a partial parotidectomy and cervical lymphadenectomy (1/35 lymph nodes positive), followed by adjuvant radiation therapy.
He enrolled in a vaccine trial (MEL-48) and received four weekly injections but developed fever and pulmonary infiltrates in week 5 and was taken off protocol. The patient was followed clinically with surveillance scans every 2 months until CT scans revealed indeterminate lung nodules, which progressed on subsequent scans. TIL were harvested from a pulmonary wedge resection. MRI of the brain also revealed new metastases, and were treated with craniotomy followed by stereotactic radiosurgery to the postoperative cavity. The patient then received one cycle of high-dose bolus IL-2 (HD IL-2), but repeat MRI of the brain showed multiple new lesions in both cerebral hemispheres. He required whole-brain radiotherapy (37.5 Gy in 15 fractions) followed by consolidative gamma knife radiosurgery to residual enhancing disease.
His systemic disease also had progressed, with new liver, spleen, omentum, and axillary lymph nodes involvement as well as enlarging bilateral pulmonary metastases. Meanwhile, the patient's systemic extracranial disease progressed rapidly as well.
One month after initiation of the IT IL-2, the patient experienced progressive weakness of the bilateral lower extremities, and an MRI of the spine revealed worsening LMD in the lumbar area, requiring palliative radiation to T12-S1.
A repeat MRI of the spine 3 weeks after radiation treatment showed further progression of the LMD, but the systemic disease remained grossly stable.
A compassionate-use investigational new drug application (CIND 10-0060) was approved by the Cancer progression outside the CNS led to small bowel obstruction, eventually requiring resection. Repeated MRI of the spine during that time showed stabilization of the LMD, with no progression of neurological symptoms, but increased generalized weakness. Table 1 Five months after the first IT TIL infusion, the patient passed away at home. 
Laboratory Data
T cells can secrete large amounts of cytokines when activated, and it was unclear whether the large number of IT T cells would lead to a "cytokine storm," poor tolerance and significant side effects. As noted, clinically we found no evidence of such an event after any of the IT TIL treatments. Levels of IFN-γ, IL-10, IL-12 p70, IL-13, IL-1β, IL-2, IL-4, IL-6, IL-8, TNF-α and TGF-β were measured in the CSF at baseline and daily for four days post-infusion for each of the three IT TIL infusions (Fig. 1A) . No appreciable elevation in the levels of IL-4, IL-12 p70, IL-13 or TGF-β were detected when measured after any of the IT TIL infusions (data not shown). IFN-γ levels, presumably produced by activated T cells, peaked after each IT TIL infusion and returned to baseline levels within 4 days. The exception was noted after the last dose, in which levels were still elevated at the last time point recorded (4 days after IT TIL infusion #2; 105 pg/ml). The peak concentration of IFN-γ induced by each TIL infusion decreased as the number of infused TIL increased (724 pg/ml after 0.3x10 9 TIL; 610 pg/ml after 1x10 9 TIL; and 474 pg/ml after 3 x10 9 TIL) (Fig. 1B) . In contrast, TNF-α and IL-1β levels peaked higher with each dose of IT TIL infused and remained markedly elevated at the last time point assessed (Fig. 1C and D) . IL-10 measurements also increased after IT TIL infusion. They reached the highest peak after the second infusion and returned to baseline levels but remained high after the last infusion (Fig.   1E) . Levels of IL-6 and IL-8 also increased significantly after each IT TIL, peaking after the last infusion and remaining high at the last time point monitored, especially with IL-8 ( Fig. 1F and   G) . Interestingly, levels of IL-6 and IL-8 peaked at a lower concentration after the second IT TIL (10) In contrast to our case, only CD8+ CTL generated in vitro using autologous dendritic cells were used.
Moreover, the IT CTLs were supported by systemic low-dose IL-2 administration, which is different from our IT IL-2 approach. Both of these cases benefitted from IT lymphocyte infusion, which resulted in at least a transient delay or reduction in the burden of the LMD. However, the treatment was unable to control the parenchymal brain disease.
IT IL-2 appears to be necessary to maintain the prolonged viability of the IT-administered cells as is the case in systemic therapy with TIL. But, as previously described, it also has an antitumor effect by itself. 
We also demonstrated that levels of several cytokines present in the CSF are consistently increasing following IT TIL and returning to baseline prior to the subsequent IT TIL infusion.
However, changes in cytokine levels in the CSF differ depending upon the cytokines tested. In our patient, we observed fluctuations in the pro-inflammatory cytokines IFNγ and TNFα following IT TIL infusion comparable to fluctuations previously observed with infusion of IT CD8+ CTL. (10) In addition, although the levels of TNFα are comparable between the two studies, we observed much higher levels of IFNγ following IT TIL as compared to the CD8+CTL infusion. In contrast to the report by Clemons-Miller, we observed vacillations in the levels of IL-10 following IT TIL infusion, whereas in their analysis, IL-10 levels did not change following CTL infusion. (10) One important concern involving patient selection for IT therapy is the status of the patient's systemic disease and performance status. Our patient suffered from very rapidly growing systemic disease, which was responsible for his worsening performance status and ultimately his death. Parenchymal disease of the brain does not respond to any intrathecal therapy and warrants management prior to or during IT therapy with other available treatment modalities.
Taken together, this suggests that patients who are candidates for IT TIL therapy should have a good performance status, controlled systemic disease or at least treatment options available.
At this point, it is also unclear how well the recent FDA agents will be able to treat or prevent the occurrence of LMD, and only a few case reports show that systemic treatment has a beneficial effect on LMD. 
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Although we cannot rule out that the patient might have derived some benefit from the initial IT IL-2 administration and radiation therapy, it appears that the addition of IT TIL might have contributed to the temporary LMD stabilization, especially since the TIL have the phenotype we previously associated with clinical response. (9) Based on this case, and taken together with our experience with IT IL-2 and systemic TIL administration, we believe that the IT TIL treatment approach for selected patients with LMD from melanoma merits further investigation in a clinical trial. We are currently developing a clinical protocol to evaluate safety and efficacy in a larger cohort of patients. Importantly, CSF analysis will be crucial to identifying predictors of clinical outcomes and to suggesting additional rational strategies. Further decline, overall generalized weakness, more pronounced lower extremity, ECOG 3 
